Cash & Equivalents
Medtronic Cash & Equivalents decreased by 10.5% to $1.15B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 7.5%, from $1.24B to $1.15B. Over 4 years (FY 2021 to FY 2025), Cash & Equivalents shows a downward trend with a -11.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.00B | $2.90B | $3.48B | $3.71B | $2.14B | $4.83B | $4.52B | $1.54B | $1.34B | $1.31B | $1.62B | $1.28B | $1.31B | $1.39B | $1.24B | $2.22B | $1.27B | $1.28B | $1.15B |
| QoQ Change | — | -3.5% | +20.0% | +6.8% | -42.4% | +125.6% | -6.4% | -65.9% | -13.2% | -2.1% | +23.8% | -20.9% | +2.1% | +6.3% | -11.0% | +78.9% | -42.6% | +0.7% | -10.5% |
| YoY Change | — | — | — | — | -28.8% | +66.5% | +30.0% | -58.5% | -37.4% | -72.8% | -64.1% | -16.8% | -2.1% | +6.3% | -23.6% | +72.7% | -2.9% | -8.0% | -7.5% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Medtronic's cash & equivalents?
- Medtronic (MDT) reported cash & equivalents of $1.15B in Q4 2025.
- How has Medtronic's cash & equivalents changed year-over-year?
- Medtronic's cash & equivalents decreased by 7.5% year-over-year, from $1.24B to $1.15B.
- What is the long-term trend for Medtronic's cash & equivalents?
- Over 4 years (2021 to 2025), Medtronic's cash & equivalents has grown at a -11.4% compound annual growth rate (CAGR), from $3.59B to $2.22B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.